TORNTPHARM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.1
| Stock Code | TORNTPHARM | Market Cap | 1,45,237 Cr. | Current Price | 4,292 ₹ | High / Low | 4,483 ₹ |
| Stock P/E | 65.0 | Book Value | 250 ₹ | Dividend Yield | 0.75 % | ROCE | 27.8 % |
| ROE | 26.2 % | Face Value | 5.00 ₹ | DMA 50 | 4,168 ₹ | DMA 200 | 3,781 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.12 % | PAT Qtr | 584 Cr. | PAT Prev Qtr | 606 Cr. |
| RSI | 51.4 | MACD | 57.5 | Volume | 2,43,707 | Avg Vol 1Wk | 4,03,393 |
| Low price | 3,075 ₹ | High price | 4,483 ₹ | PEG Ratio | 2.67 | Debt to equity | 0.25 |
| 52w Index | 86.4 % | Qtr Profit Var | 20.4 % | EPS | 65.0 ₹ | Industry PE | 27.6 |
📊 Analysis: TORNTPHARM shows strong intraday potential today. RSI at 51.4 indicates neutral-to-positive momentum, while MACD (57.5) is bullish, confirming upward bias. The stock is trading above both 50 DMA (4,168 ₹) and 200 DMA (3,781 ₹), reflecting short- and medium-term strength. Volume (2.43 lakh) is lower than the 1-week average (4.03 lakh), which slightly limits intraday participation, but fundamentals remain robust.
💹 Optimal Buy Price: 4,250–4,290 ₹ (near current support zone).
🎯 Profit-Taking Levels: 4,340 ₹ (first resistance), 4,400–4,450 ₹ (next resistance zone).
🛑 Stop-Loss: 4,200 ₹ (protective support).
📈 If Already Holding: Exit intraday if price fails to sustain above 4,250 ₹ with weakening momentum or volume. Protective exit below 4,200 ₹. Book partial profits near 4,340–4,450 ₹ if momentum sustains.
Positive
- Strong fundamentals: EPS at 65.0 ₹, ROE 26.2%, ROCE 27.8%.
- MACD positive (57.5), confirming bullish bias.
- Stock trading above both 50 DMA and 200 DMA, showing technical strength.
- FII holdings increased (+0.21%), reflecting foreign investor confidence.
- PEG ratio at 2.67 indicates reasonable growth-adjusted valuation.
Limitation
- High P/E (65.0) compared to industry PE (27.6), showing premium valuation.
- Quarterly PAT declined slightly (584 Cr. vs 606 Cr.).
- Volume below average, limiting intraday momentum.
- Debt-to-equity ratio at 0.25, though manageable, adds some leverage risk.
Company Negative News
- DII holdings decreased (-0.12%), showing reduced domestic institutional support.
- Sequential PAT dropped marginally, raising short-term caution.
Company Positive News
- Strong EPS and consistent profitability.
- FII support increased, reflecting foreign confidence.
- Stock near 52-week high (4,483 ₹), showing strong investor sentiment.
Industry
- Industry PE at 27.6, while TORNTPHARM trades at 65.0, indicating premium valuation.
- Pharma sector remains resilient with long-term growth prospects, though valuations are stretched.
Conclusion
⚖️ TORNTPHARM earns a strong intraday rating (4.1). Positive MACD, strong fundamentals, and support above DMA levels favor bullish bias. Best strategy: Buy near 4,250–4,290 ₹, target 4,340–4,450 ₹, and protect downside at 4,200 ₹. Intraday traders can consider quick profit booking near resistance levels while maintaining caution around premium valuations.
Selva, TORNTPHARM looks technically stronger than TITAN and RAMCOCEM, with bullish confirmation from MACD and RSI. Would you like me to prepare a basket overlay comparing TORNTPHARM with peers like Sun Pharma, Cipla, and Dr. Reddy’s to see if intraday capital rotation favors TORNTPHARM or stronger pharma setups?